Published in AIDS on November 01, 2007
The Spectrum projection package: improvements in estimating mortality, ART needs, PMTCT impact and uncertainty bounds. Sex Transm Infect (2008) 5.98
Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect (2008) 2.49
Changes in the distribution of HIV type 1 subtypes D and A in Rakai District, Uganda between 1994 and 2002. AIDS Res Hum Retroviruses (2010) 1.28
Increased rate of CD4+ T-cell decline and faster time to antiretroviral therapy in HIV-1 subtype CRF01_AE infected seroconverters in Singapore. PLoS One (2011) 1.10
Identification and genetic characterization of a novel CRF22_01A1 recombinant form of HIV type 1 in Cameroon. AIDS Res Hum Retroviruses (2010) 0.99
Evidence that HIV-1 CRF01_AE is associated with low CD4+T cell count and CXCR4 co-receptor usage in recently infected young men who have sex with men (MSM) in Shanghai, China. PLoS One (2014) 0.94
A novel immunodominant CD8+ T cell response restricted by a common HLA-C allele targets a conserved region of Gag HIV-1 clade CRF01_AE infected Thais. PLoS One (2011) 0.83
Exploring Thailand's mortality transition with the aid of life tables. Asia Pac Viewp (2011) 0.80
Continuous spread of HIV-1 subtypes D and CRF01_AE in France from 2003 to 2009. J Clin Microbiol (2012) 0.80
HIV type 1 polymerase gene polymorphisms are associated with phenotypic differences in replication capacity and disease progression. J Infect Dis (2013) 0.79
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst (2003) 2.81
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71
Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect (2008) 2.49
Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr (2002) 2.48
Modifications of a large HIV prevention clinical trial to fit changing realities: a case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in Lilongwe, Malawi. Contemp Clin Trials (2008) 2.35
Efficacy of the female condom as a barrier to semen during intercourse. Am J Epidemiol (2003) 2.20
Partner characteristics, intensity of the intercourse, and semen exposure during use of the female condom. Am J Epidemiol (2003) 1.92
The acceptability of the female and male condom: a randomized crossover trial. Perspect Sex Reprod Health (2004) 1.90
Maternal mortality among Afghan refugees in Pakistan, 1999-2000. Lancet (2002) 1.74
Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest (2011) 1.73
The use of nonhuman primate models in HIV vaccine development. PLoS Med (2008) 1.73
Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis (2003) 1.71
Identification of CRF34_01B, a second circulating recombinant form unrelated to and more complex than CRF15_01B, among injecting drug users in northern Thailand. AIDS Res Hum Retroviruses (2007) 1.69
A new circulating recombinant form, CRF15_01B, reinforces the linkage between IDU and heterosexual epidemics in Thailand. AIDS Res Hum Retroviruses (2003) 1.64
Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS (2010) 1.63
Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Dis (2003) 1.57
The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol (2009) 1.56
HIV prevalence and risks among injection and noninjection drug users in northern Thailand: need for comprehensive HIV prevention programs. J Acquir Immune Defic Syndr (2003) 1.53
A comparison of women's regret after vasectomy versus tubal sterilization. Obstet Gynecol (2002) 1.50
Drug use, increasing incarceration rates, and prison-associated HIV risks in Thailand. AIDS Behav (2003) 1.46
Safe conception for HIV-discordant couples: insemination with processed semen from the HIV-infected partner. Am J Obstet Gynecol (2013) 1.45
Seroprevalence of human herpesvirus 8 infection in Northern Thailand. Clin Infect Dis (2004) 1.45
Involving communities in the design of clinical trial protocols: the BAN Study in Lilongwe, Malawi. Contemp Clin Trials (2006) 1.45
A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr (2007) 1.39
Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. J Low Genit Tract Dis (2007) 1.37
High HIV, hepatitis C and sexual risks among drug-using men who have sex with men in northern Thailand. AIDS (2005) 1.36
High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding. Obstet Gynecol (2010) 1.31
Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer (2006) 1.28
Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis (2003) 1.28
Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroads. J Acquir Immune Defic Syndr (2008) 1.26
Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One (2012) 1.25
The changing molecular epidemiology of HIV type 1 among northern Thai drug users, 1999 to 2002. AIDS Res Hum Retroviruses (2004) 1.22
Breast milk and HIV-1: vector of transmission or vehicle of protection? Lancet Infect Dis (2003) 1.20
Efficacy of the male latex condom and of the female polyurethane condom as barriers to semen during intercourse: a randomized clinical trial. Am J Epidemiol (2007) 1.20
Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women. Am J Epidemiol (2006) 1.20
HIV voluntary counseling and testing and HIV incidence in male injecting drug users in northern Thailand: evidence of an urgent need for HIV prevention. J Acquir Immune Defic Syndr (2006) 1.17
Hepatitis C infection among drug users in northern Thailand. Am J Trop Med Hyg (2006) 1.14
Self-reported mechanical problems during condom use and semen exposure. Comparison of two randomized trials in the United States of America and Brazil. Sex Transm Dis (2007) 1.13
Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. Am J Obstet Gynecol (2002) 1.12
Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS One (2010) 1.09
Evaluating nurses' implementation of an infant-feeding counseling protocol for HIV-infected mothers: The Ban Study in Lilongwe, Malawi. AIDS Educ Prev (2009) 1.07
Vulvar, vaginal, and perianal intraepithelial neoplasia in women with or at risk for human immunodeficiency virus. Obstet Gynecol (2006) 1.06
Effect of contraceptive methods on natural history of HIV: studies from the Mombasa cohort. J Acquir Immune Defic Syndr (2005) 1.06
Broad human immunodeficiency virus (HIV)-specific T cell responses to conserved HIV proteins in HIV-seronegative women highly exposed to a single HIV-infected partner. J Infect Dis (2003) 1.05
Risk factors associated with injection initiation among drug users in Northern Thailand. Harm Reduct J (2006) 1.03
The risk of pregnancy after vasectomy. Obstet Gynecol (2004) 1.00
Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles. PLoS Pathog (2011) 1.00
Human immunodeficiency virus (HIV)-specific antibody in cervicovaginal lavage specimens obtained from women infected with HIV type 1. Clin Infect Dis (2002) 0.97
T-lymphocyte profile and total and virus-specific immunoglobulin concentrations in the cervix of HIV-1-infected women. J Acquir Immune Defic Syndr (2007) 0.97
Douching beliefs and practices among black and white women. J Womens Health Gend Based Med (2002) 0.94
Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study. AIDS (2011) 0.94
The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis (2002) 0.93
Predictors of mortality among injecting and non-injecting HIV-negative drug users in northern Thailand. Addiction (2007) 0.93
Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults. AIDS Res Hum Retroviruses (2010) 0.93
Reasons for testing and clinical and demographic profile of adolescents with non-perinatally acquired HIV infection. Pediatrics (2006) 0.93
Viral load and CD4 count dynamics after HIV-1 seroconversion in homosexual and bisexual men in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr (2006) 0.92
Accuracy of Papanicolaou test among HIV-infected women. Clin Infect Dis (2006) 0.92
Vaginal flora morphotypic profiles and assessment of bacterial vaginosis in women at risk for HIV infection. Infect Dis Obstet Gynecol (2005) 0.92
Hepatitis C virus (HCV) core antigen assay to detect ongoing HCV infection in thai injection drug users. J Clin Microbiol (2004) 0.91
Behavioral and social issues among volunteers in a preventive HIV vaccine trial in Thailand. J Acquir Immune Defic Syndr (2005) 0.90
Reproductive options for HIV-serodiscordant couples. AIDS Rev (2006) 0.90
Comparing Measures of Late HIV Diagnosis in Washington State. AIDS Res Treat (2011) 0.89
Breast milk CD4+ T cells express high levels of C chemokine receptor 5 and CXC chemokine receptor 4 and are preserved in HIV-infected mothers receiving highly active antiretroviral therapy. J Infect Dis (2007) 0.89
Safe conception for HIV discordant couples through sperm-washing: experience and perceptions of patients in Milan, Italy. Reprod Health Matters (2008) 0.88
Predictors of low CD4 count in resource-limited settings: based on an antiretroviral-naive heterosexual thai population. J Acquir Immune Defic Syndr (2005) 0.87
Temporal trends in the prevalence of HIV and other transfusion-transmissible infections among blood donors in northern Thailand, 1990 through 2001. Transfusion (2003) 0.86
Nutritional biomarkers associated with gynecological conditions among US women with or at risk of HIV infection. Am J Clin Nutr (2007) 0.85
Implications of blood contamination for assessment of local cellular immunity in the endocervix. AIDS Res Hum Retroviruses (2004) 0.84
Translating guidelines to practice: findings from a multidisciplinary preventive cardiology programme in the west of Ireland. Eur J Prev Cardiol (2013) 0.82
Coreceptor utilization of HIV type 1 subtype E viral isolates from Thai men with HIV type 1-infected and uninfected wives. AIDS Res Hum Retroviruses (2002) 0.82
The potential role of biomarkers in HIV preventive vaccine trials. J Acquir Immune Defic Syndr (2009) 0.81
Frequencies of IL10 SNP genotypes by multiplex PCR-SSP and their association with viral load and CD4 counts in HIV-1-infected Thais. Asian Pac J Allergy Immunol (2011) 0.80
High prevalence of self-reported forced sexual intercourse among internally displaced women in Azerbaijan. Am J Public Health (2003) 0.80
Abnormal vaginal cytology in HIV-infected and at-risk women after hysterectomy. J Acquir Immune Defic Syndr (2004) 0.79
Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop. J Acquir Immune Defic Syndr (2007) 0.79
HIV infection among female drug users in Northern Thailand. Drug Alcohol Depend (2004) 0.79
Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition. AIDS (2016) 0.78
Do women with HIV infection have different indications for hysterectomy? J Acquir Immune Defic Syndr (2005) 0.78
HIV-discordant couples and parenthood: how are we dealing with the risk of transmission? AIDS (2006) 0.77
Reply to Richie and Villasante. J Infect Dis (2012) 0.77
Lymphocyte homeostasis in HIV-infected northern Thais. AIDS Res Hum Retroviruses (2004) 0.76
HIV vaccine efficacy trials: towards the future of HIV prevention. Infect Dis Clin North Am (2007) 0.76
Prevention of perinatal HIV transmission: a review of novel strategies. Expert Opin Investig Drugs (2003) 0.75
HIV treatment as prevention: [corrected] next steps. Curr Opin HIV AIDS (2012) 0.75